GlassScriptPhysician profile
Felix Sokolsky
NPI 1386620706
$2,452.92
in general payments reported to CMS, 2019-2025
22 companies · $612 in 2025
The $612 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $16.11 · 2021: $98.24 · 2022: $168 · 2023: $687 · 2024: $554 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,851.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $363.52 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Novo Nordisk INC | $283.02 | 2019-2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $264.54 | 2022-2025 | Airsupra, Farxiga |
| Teva Pharmaceuticals USA, INC. | $234.75 | 2023-2025 | Uzedy, Austedo Xr |
| Lundbeck LLC | $213.65 | 2023-2025 | Rexulti |
| Alkermes, INC. | $171.66 | 2023-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $166.75 | 2023-2025 | Caplyta |
| Abbvie INC. | $147.69 | 2023-2025 | Ubrelvy |
| Glaxosmithkline, LLC. | $103.98 | 2019-2023 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $89.93 | 2021-2023 | Trintellix |
| Sunovion Pharmaceuticals INC. | $74.11 | 2021 | |
| Amgen INC. | $57.30 | 2023-2025 | Otezla, Repatha, Otezla |
| Tactile Systems Technology INC | $57.14 | 2019 | |
| Ironshore Pharmaceuticals INC. | $47.56 | 2023 | Jornay Pm |
| Axsome Therapeutics, INC. | $31.90 | 2023 | Auvelity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $28.33 | 2024 | Fanapt |
| Janssen Pharmaceuticals, INC | $27.77 | 2023 | Invega Trinza, Invega Sustenna, Invega |
| Lilly USA, LLC | $24.43 | 2025 | Mounjaro, Zepbound |
| Regeneron Healthcare Solutions, INC. | $17.96 | 2024 | Evkeeza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.11 | 2020 | |
| Indivior INC. | $15.91 | 2024 | Perseris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.91 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felix Sokolsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.